Cytokinetics, Incorporated
CYTK
$74.13
$0.680.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 67.67M | 105.82M | 88.04M | 87.21M | 85.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.67M | 105.82M | 88.04M | 87.21M | 85.74M |
| Cost of Revenue | 405.11M | 414.26M | 416.03M | 405.26M | 390.64M |
| Gross Profit | -337.44M | -308.45M | -327.99M | -318.05M | -304.90M |
| SG&A Expenses | 370.47M | 331.80M | 284.27M | 254.89M | 242.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 775.58M | 746.06M | 700.30M | 660.14M | 632.72M |
| Operating Income | -707.91M | -640.25M | -612.26M | -572.93M | -546.98M |
| Income Before Tax | -894.00M | -829.61M | -784.96M | -751.94M | -606.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -894.00 | -829.61 | -784.96 | -751.94 | -606.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -894.00M | -829.61M | -784.96M | -751.94M | -606.31M |
| EBIT | -707.91M | -640.25M | -612.26M | -572.93M | -546.98M |
| EBITDA | -695.36M | -629.04M | -602.13M | -563.29M | -537.60M |
| EPS Basic | -7.25 | -6.87 | -6.56 | -6.31 | -5.12 |
| Normalized Basic EPS | -3.90 | -3.66 | -3.47 | -3.31 | -3.20 |
| EPS Diluted | -7.25 | -6.87 | -6.56 | -6.31 | -5.12 |
| Normalized Diluted EPS | -3.90 | -3.66 | -3.47 | -3.31 | -3.20 |
| Average Basic Shares Outstanding | 495.44M | 482.82M | 478.04M | 476.01M | 473.71M |
| Average Diluted Shares Outstanding | 495.44M | 482.82M | 478.04M | 476.01M | 473.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |